Machine Learning Discovers New Antimicrobial Peptides That Kill Drug-Resistant Bacteria

Two ML-identified peptides (GDST-038 and GDST-045) killed ESKAPE pathogens, achieved >3-log reduction in biofilm bacteria, eliminated S. aureus in 3D human skin models at ≥15 μM, and resisted bacterial resistance development through 22 passages.

Machine learning-based screening of 16,384 peptide sequences using CalcAMP model, followed by in vitro antimicrobial testing against MDR bacteria, biofilm killing assays, hemolysis testing, 3D human skin infection model, and 22-passage resistance development assessment.

Antibiotic resistance is projected to kill millions annually by 2050. Traditional antibiotic discovery takes years and billions of dollars. Using machine learning to rapidly identify effective antimicrobial peptides — ones that bacteria struggle to develop resistance against — could dramatically accelerate the pipeline of new anti-infective treatments.

Antimicrobial peptides have long been seen as promising but difficult to develop. Machine learning is now making it practical to search enormous peptide sequence spaces quickly. The fact that these AI-discovered peptides avoid triggering resistance after 22 passages is particularly significant — resistance to conventional antibiotics often emerges within a handful of exposures.

Testing has been limited to in vitro and 3D skin model settings — no animal or human trials yet. The 14-amino-acid peptides may face stability and delivery challenges in vivo. Hemolysis was minimal but needs to be confirmed at therapeutic doses in living systems. Long-term resistance potential beyond 22 passages is unknown.